Viatris Inc. (VTRS) earnings on August 6, 2026
Prior outlook: Pessimistic Outcome: Accurate
Viatris shares settled down -7.85% after reaching an intraday low of -8.02%, despite reporting Q2 adjusted EPS and sales that beat estimates and raising FY2026 guidance. The significant decline suggests the market may have reacted to other factors or that the positive news was already anticipated.
VTRS price around the earnings
16.29
Change: -7.6%
2026-08-06, 20:00 UTC
Start of the measured window
End of the measured window
16.25
16.93
17.62
18.30
17.64
August 6, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Pessimistic Outcome: Accurate
- Thesis published
- Results released
Strong past earnings and regulatory catalyst, but analyst upside is minimal, suggesting news is priced in.
Context analyzed before publication
- Trend
- Trajectory collapsed from 38.1 to -20.5, indicating significant deterioration; strong earnings history and regulatory ca
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 2.2
- Analysts covering the stock
- 8
- Average price target
- 17.94
- Lowest price target
- 12
- Highest price target
- 23
- Upside to price target
- 1.6%
- Revenue growth
- 8.1%
- Forward EPS
- 2.63
- Trailing EPS
- -0.3
- Analyst moves in the last 60 days
- 0
- Strong buy: 1
- Buy: 4
- Hold: 4
- Sell: 0
- Strong sell: 1
- Strong buy
- 1
- Buy
- 4
- Hold
- 4
- Sell
- 0
- Strong sell
- 1
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
News
Sources (2)
- Viatris Receives EMA CHMP Recommendation For Approval Of Ruxolitinib Viatris For The Treatment Of Myelofibrosis, Polycythaemia Vera And Graft-Vs-Host Disease (opens in a new tab) — Benzinga
- Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields (opens in a new tab) — Benzinga
Technicals
Evidence
- Price when the context was analyzed
- 17.64
- Average true range (ATR)
- 2.4%
- Distance to 52-week high
- -1.2%
- 14-day change (14d)
- +3.6%
- 30-day change (30d)
- +5.0%
- 30-day relative strength
- +2.6%
- SPY change (30d)
- +2.5%
- Nearest support
- 17.51
- Distance to nearest support
- 0.7%
- Nearest resistance
- 17.66
- Distance to nearest resistance
- 0.1%
- Volume accumulation ratio (14d / 46d)
- 0.88
- Mid: 17.51 (0.7% away, 0.31 ATR, 21 touches)
- Minor: 17.3 (1.9% away, 0.81 ATR, 6 touches)
- Mid: 17.18 (2.6% away, 1.1 ATR, 15 touches)
- Mid: 17.66 (0.1% away, 0.06 ATR, 19 touches)
- Minor: 17.86 (1.3% away, 0.55 ATR, 4 touches)
- Mid: 18.07 (2.4% away, 1.03 ATR, 4 touches)
Trends
Evidence
- Average earnings surprise
- +11.3%
- May 7, 2026: actual EPS 0.59 vs estimate 0.5 (surprise +17.5%)
- February 26, 2026: actual EPS 0.57 vs estimate 0.53 (surprise +7.4%)
- November 6, 2025: actual EPS 0.67 vs estimate 0.62 (surprise +8.5%)
- August 7, 2025: actual EPS 0.62 vs estimate 0.56 (surprise +11.6%)
Expected move
- Implied move
- +2.8%
- Source
- Options chain
Reactions over its last 20 earnings
- Median move
- 6.2%
- 75th percentile move
- 7.8%
- 90th percentile move
- 13.8%
- Up / down moves
- 13 / 7
- Average up move
- +6.8%
- Average down move
- -9.4%
Monitoring and close
What Viatris Inc. reported
- Status
- Finished
| Actual EPS | 0.69 |
|---|---|
| EPS estimate | 0.6 |
| EPS surprise | +15.0% |
| Revenue | $3,756 million |
| Revenue estimate | $3,675 million |
| Revenue surprise | +2.2% |
Viatris beat Q2 expectations, driven by China. The Tyrvaya sale to Harrow sharpens focus and raises 2026 outlook, keeping an optimistic tone.
Sources (11)
- Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook (opens in a new tab) — Benzinga
- VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump (opens in a new tab) — Zacks
- Viatris Inc. 2026 Q2 - Results - Earnings Call Presentation (opens in a new tab) — SeekingAlpha
- Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics (opens in a new tab) — Zacks
- Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates (opens in a new tab) — Zacks
- Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026 (opens in a new tab) — Yahoo
- Viatris beat expectations with adjusted earnings of $0.69 per share and sales of $3.756 billion, above forecasts. — Benzinga
- Viatris Q2 Adj. EPS $0.69 Beats $0.60 Estimate, Sales $3.756B Beat $3.675B Estimate (opens in a new tab) — Benzinga
- Viatris Raises FY2026 Adj EPS Guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 Est; Raises FY2026 Sales Guidance from $14.450B-$14.950B to $14.550B-$14.950B vs $14.783B Est (opens in a new tab) — Benzinga
- Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease (opens in a new tab) — Yahoo
- Viatris Reports Second-Quarter 2026 Financial Results (opens in a new tab) — Yahoo
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, results beat expectations on both earnings and revenue, and the price is indicating +2.7% pre-market, a move below the stock's usual reaction (about 6%). The figures don't confirm the prior scenario: the comparable cases aren't consistent enough.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- -7.8%
- Max favorable move (MFE)
- 8%
- Max adverse move (MAE)
- 4.3%